Trial site
CHRISTUS St. Vincent Regional Cancer Center
Santa Fe, New Mexico 87505, United StatesNot linked to an institution yet
- 11running trials
- 1closed trial
The trials here
What the 12 trials at this site are about, from their registry records.
- Phase
- Phase 37 trials
- Phase 22 trials
- Phase 11 trial
- Phase 1/21 trial
- Phase 2/31 trial
- Status
- Recruiting9 trials
- Active, not recruiting2 trials
- Completed1 trial
- Lead sponsor
- Pfizer3 trials
- ImmunoVaccine Technologies, Inc. (IMV Inc.)2 trials
- Janssen Research & Development, LLC2 trials
- BeOne Medicines1 trial
- Inhibrx Biosciences, Inc1 trial
- and 3 more
Running trials
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· Phase 3· Pfizer· Source
Recruiting
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
NCT07157033· Phase 1/2· Xerient Pharma· Source
Contact: Tamara Flys, PhD
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· Phase 3· Pfizer· Source
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872· Phase 3· BeOne Medicines· Source
Contact: Study Director
Recruiting
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779· Phase 3· Pfizer· Source
Recruiting
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
NCT06295731· Phase 2/3· Inhibrx Biosciences, Inc· Source
Contact: Andrea Teague, MD (principal investigator)
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04920617· Phase 2· ImmunoVaccine Technologies, Inc. (IMV Inc.)· Source
Contact: Doreen Padilla
Active, not recruiting
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
NCT03589339· Phase 1· Nanobiotix· Source
Active, not recruiting
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
NCT03836352· Phase 2· ImmunoVaccine Technologies, Inc. (IMV Inc.)· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error